

# ATLAS GPT (ALT) TEST



(Kinetic)

For *In-Vitro* and professional use only  
Store at 2-8°C

## PRINCIPLE OF THE METHOD

Alanine aminotransferase (ALT) o Glutamate pyruvate transaminase (GPT) catalyses the reversible transfer of an amino group from alanine to  $\alpha$ -ketoglutarate forming glutamate and piruvate.

The piruvate produced is reduced to lactate by lactate dehydrogenase (LDH) and NADH:



The rate of decrease in concentration of NADH, measured photometrically, is proportional to the catalytic concentration of ALT present in the sample.

## CLINICAL SIGNIFICANCE

The ALT is a cellular enzyme, found in highest concentration in liver and kidney. High levels are observed in hepatic disease like hepatitis, diseases of muscles and traumatisms, its better application is in the diagnosis of the diseases of the liver.

When they are used in conjunction with AST aid in the diagnosis of infarcts in the myocardium, since the value of the ALT stays within the normal limits in the presence of elevated levels of AST.

Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data.

## REAGENTS

|                         |                             |             |
|-------------------------|-----------------------------|-------------|
| <b>R 1</b><br>Buffer    | TRIS pH 7.8                 | 100 mmol/L  |
|                         | L-Alanine                   | 500 mmol/L  |
| <b>R 2</b><br>Substrate | NADH                        | 0.18 mmol/L |
|                         | Lactate dehydrogenase (LDH) | 1200 U/L    |
|                         | $\alpha$ -Ketoglutarate     | 15 mmol/L   |

## PREPARATION

Working reagent (WR):

Dissolve one tablet of R2 Substrate in 2 mL of R1.

Cap and mix gently to dissolve contents.

Stability: 21 days at 2-8°C or 72 hours at room temperature (15-25°C).

## STORAGE AND STABILITY

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8°C, protected from light and contaminations prevented during their use.

Do not use the tablets if appears broken.

Do not use reagents over the expiration date.

### Signs of reagent deterioration:

- Presence of particles and turbidity.
- Blank absorbance (A) at 340 nm < 1.00.

## ADDITIONAL EQUIPMENT

- Spectrophotometer or colorimeter measuring at 340 nm.
- Thermostatic bath at

25°C, 30°C, 37°C ( $\pm 0.1^\circ\text{C}$ ). - Matched cuvettes 1.0 cm light path.  
- General laboratory equipment.

## SAMPLES

Serum or plasma: Stability 7 days at 2-8°C..

## PROCEDURE

- Assay conditions:  
Wavelength: .....340 nm  
Cuvette :.....1 cm light path  
Constant temperature .....25°C / 30°C / 37°C
- Adjust the instrument to zero with distilled water or air.
- Pipette into a cuvette:

|                          |     |
|--------------------------|-----|
| WR (mL)                  | 1.0 |
| Sample ( $\mu\text{L}$ ) | 100 |

- Mix, incubate for 1 minute.
- Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1-minute intervals thereafter for 3 minutes.
- Calculate the difference between absorbances and the average absorbance differences per minute ( $\Delta A/\text{min}$ ).

## CALCULATIONS

$$\Delta A/\text{min} \times 1750 = \text{U/L of ALT}$$

**Units:** One international unit (IU) is the amount of enzyme that transforms 1  $\mu\text{mol}$  of substrate per minute, in standard conditions. The concentration is expressed in units per liter of sample (U/L).

## Temperature conversion factors

To correct results to other temperatures multiply by:

| Assay temperature | Conversion factor to |      |      |
|-------------------|----------------------|------|------|
|                   | 25°C                 | 30°C | 37°C |
| 25°C              | 1.00                 | 1.32 | 1.82 |
| 30°C              | 0.76                 | 1.00 | 1.39 |
| 37°C              | 0.55                 | 0.72 | 1.00 |

## QUALITY CONTROL

Control sera are recommended to monitor the performance of assay procedures.

If control values are found outside the defined range, check the instrument, reagents and technique for problems.

Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable **tolerances**.

## REFERENCE VALUES<sup>4/5</sup>

|       |              |        |        |
|-------|--------------|--------|--------|
|       | 25°C         | 30°C   | 37°C   |
| Men   | up to 22 U/L | 29 U/L | 40 U/L |
| Women | up to 18 U/L | 22 U/L | 32 U/L |

Normal newborns have been reported to show a reference range of up to double the adult, attributed to the neonate's hepatocytes. These values decline to adult levels by approximately 3 months of age.

These values are for orientation purpose; each laboratory should establish its own reference range.

## PERFORMANCE CHARACTERISTICS

**Measuring range:** From *detection limit* of 1,20 U/L to *linearity limit* of 262 U/L. If the results obtained were greater than linearity limit, dilute the sample 1/10 with NaCl 9 g/L and multiply the result by 10.

**Precision:**

|          | Intra-assay (n=20) |       |
|----------|--------------------|-------|
| Mean U/L | 34.9               | 118.4 |
| SD       | 0.64               | 1.17  |
| CV (%)   | 1.84               | 0.99  |

| Inter-assay (n=20) |       |
|--------------------|-------|
| 34.1               | 118.3 |
| 1.03               | 1.53  |
| 3.04               | 1.29  |

*Sensitivity:* 1 U/L = 0.000557 ΔA / min.

*Accuracy:* Results obtained using ATLAS reagents (y) did not show systematic differences when compared with other commercial reagents (x). The results obtained using 50 samples were the following:

Correlation coefficient (r): 0.99.

Regression equation:  $y = 0.98x + 0.38$ .

The results of the performance characteristics depend on the analyzer used.

### **INTERFERENCES**

Anticoagulants currently in use like heparin, EDTA, oxalate and fluoride do not affect the results. Hemolysis interferes with the assay.

A list of drugs and other interfering substances with ALT determination has been reported by Young et al.

### **BIBLIOGRAPHY**

1. Murray R. Alanine aminotransferase. Kaplan A et al. Clin Chem The C.V. Mosby Co. St Louis. Toronto, Princeton 1984; 1088-1090.
2. Young DS. Effects of drugs on Clinical Lab. Tests, 4th ed AACC Press, 1995.
3. Young DS. Effects of disease on Clinical Lab. Tests, 4th ed AACC 2001.
4. Burtis A et al. Tietz Textbook of Clinical Chemistry, 3rd ed AACC 1999.
5. Tietz N W et al. Clinical Guide to Laboratory Tests, 3rd ed AACC 1995.

### **Atlas Medical**

William James House,  
Cowley Road, Cambridge, CB4 0WX, UK  
Tel: ++44 (0) 1223 858 910  
Fax: ++44 (0) 1223 858 524  
PPI194A01  
Revision A (02.07.2005)